𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial

✍ Scribed by Teemu J. Murtola; Teuvo L.J. Tammela; Liisa Määttänen; Heini Huhtala; Elizabeth A. Platz; Martti Ala-Opas; Ulf-Håkan Stenman; Anssi Auvinen

Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
177 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Decreased risk of advanced prostate cancer has been reported among men using statins. However, the evidence on overall prostate cancer risk is conflicting. We compared the relative risk between current users and non‐users of statins or other cholesterol‐lowering medications in a population undergoing systematical prostate cancer screening. The study cohort comprised of 23,320 men participating in the screening arm of the Finnish prostate cancer screening trial during 1996–2004. Information on medication use was obtained from a comprehensive national prescription database. Cox proportional hazards regression was used to calculate multivariable adjusted hazard ratios (HRs) for prostate cancer. Serum prostate‐specific antigen (PSA) level was compared between current users and non‐users of cholesterol‐lowering drugs. Compared with medication non‐users, the overall prostate cancer incidence was decreased among statin users [HR 0.75, 95% confidence interval (CI) 0.63–0.89]. The inverse association was dose‐dependent with cumulative amount of statin use, and strongest for low‐grade and early stage tumors. The incidence was nonsignificantly lower also among users of other types of cholesterol‐lowering drugs (HR 0.62, 95% CI 0.28–1.38), but without dose‐dependence. Age‐adjusted median serum PSA tended to be lower among users of cholesterol‐lowering drugs, but the relative risk decrease among statin users was not related to decreased PSA. Overall incidence of prostate cancer was lowered among statin users when bias due to differential PSA testing between medication users and non‐users was eliminated by systematical prostate cancer screening. Cholesterol‐lowering with statins seems beneficial for prostate cancer prevention.

📜 SIMILAR VOLUMES

Biological aggressiveness of prostate ca
Biological aggressiveness of prostate cancer in the Finnish screening trial
✍ Marita Laurila; Teuvo L.J. Tammela; Anssi Auvinen; Jorma Isola; Tapio Visakorpi; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 184 KB

## Abstract Prostate cancer aggressiveness was evaluated based on pathologic characterization of cases detected in the Finnish prostate cancer screening trial. The trial population consists of 80,458 men aged 55–67 years. A total of 32,000 men were randomized to the screening arm. The remaining 48,

Test sensitivity of prostate-specific an
Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial
✍ Anssi Auvinen; Liisa Määttänen; Patrik Finne; Ulf-Håkan Stenman; Jussi Aro; Harr 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 77 KB

## Abstract We estimated the sensitivity of serum prostate‐specific antigen (PSA) as a screening test for prostate cancer in the Finnish randomised, population‐based prostate cancer screening trial. The study population consisted of 80,458 men aged 55–67 years identified from the national populatio

Large-scale randomized prostate cancer s
Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial
✍ Harry J. de Koning; Anssi Auvinen; Antonio Berenguer Sanchez; Fernando Calais da 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 79 KB 👁 2 views

## Abstract Two large‐scale randomized screening trials, the Prostate, Lung, Colorectal and Ovary (PLCO) cancer trial in the USA and the European Randomized Screening for Prostate Cancer (ERSPC) trial in Europe are currently under way, aimed at assessing whether screening reduces prostate cancer mo

IGF-1 and IGFBP-3: Risk of prostate canc
IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
✍ Jocelyn M. Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R. Fears; Nilanjan Chatte 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 91 KB 👁 1 views

## Abstract IGF‐1 and IGFBP‐3 may influence risk of prostate cancer through their roles in cellular growth, metabolism and apoptosis, however, epidemiologic results have been inconsistent. The role of obesity in prostate cancer risk is not clearly understood, but hyperinsulinemia‐related increases

Algorithms based on prostate-specific an
Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-postitive PSA results in prostate cancer screening
✍ Patrik Finne; Ralf Finne; Chris Bangma; Jonas Hugosson; Matti Hakama; Anssi Auvi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB

## Abstract Our objective was to determine whether multivariate algorithms based on serum total PSA, the free proportion of PSA, age, digital rectal examination and prostate volume can reduce the rate of false‐positive PSA results in prostate cancer screening more effectively than the proportion of

Trichomonosis and subsequent risk of pro
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial
✍ Siobhan Sutcliffe; John F. Alderete; Cathee Till; Phyllis J. Goodman; Ann W. Hsi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 94 KB

## Abstract We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan, __Trichomonas vaginalis__, and prostate cancer risk in the Health Professionals Follow‐up Study. To determine the reproducibility of this finding,